Your healthcare provider will tailor your dose so that you are taking a dose that is effective with the least amount of side effects
nausea was the single most common complaint (14.1%), followed by diarrhea (4.7%)
Acrolein contributes strongly to antimicrobial and heterocyclic amine transformation activities of reuterin
A reduction in hydrochloric acid and/or digestive enzyme insufficiency, common in the ageing population could contribute to low levels
The original GLP-1 receptor agonist was exenatide, which was first synthesised in 1996
Primary composite end point 2 : Time from randomization to first occurrence of a 3-part composite MACE, defined as CV death, non-fatal MI, or non-fatal stroke Key secondary end points 2 : Time from randomization to first occurrence of: Cardiovascular death All-cause death Other secondary end points 2 : Time from randomization to first occurrence of: Fatal or non-fatal myocardial infarction Fatal or non-fatal stroke Relevant supportive secondary end points 2 : Change in body weight from baseline to week 104 Change in waist circumference from baseline to week 104 Change in systolic blood pressure from baseline to week 104 Change in diastolic blood pressure from baseline to week 104 Change in heart rate from baseline to week 104 Change in A1c from baseline to week 104 Change in lipids from baseline to week 104 LDL, HDL, triglycerides, and total cholesterol
